Evommune EVMN
NYSE EVMN
$8.64 +0.80 (+10.14%)
As of: Nov 11, 2026 · 3:59 PM EST

Evommune (EVMN) Preferred Stock Liabilities (2024 - 2025)

Updated

Evommune's Preferred Stock Liabilities came in at $257 million for Q3 2025, up 72.1% from $149.37 million a year earlier and unchanged from the prior quarter.

Analysis

Evommune (EVMN) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends

At the end of FY2024, Evommune's Preferred Stock Liabilities was $191.78 million.

  • Business Quant data shows EVMN's Preferred Stock Liabilities at $257 million (Q2 2025), $191.78 million (Q1 2025) and $191.78 million (Q4 2024) in the three quarters before Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Evommune 285.17 Mn -352.34 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 257.00 Mn
Jun 30, 2025 257.00 Mn
Mar 31, 2025 191.78 Mn
Dec 31, 2024 191.78 Mn
Sep 30, 2024 149.37 Mn
API Access

Evommune Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=EVMN&period=max&api_key=YOUR_API_KEY